Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a new type of drug used to treat diabetes.
A recent study from FDA showed that the drugs could lead to a type of infection in the body, including external genitalia, perineum, and perianal region.
The infection was called Fournier gangrene.
The researchers examined the health risks of SGLT2 inhibitors and other diabetes drugs, including metformin, insulin glargine, short-acting insulin, sitagliptin plus metformin, and dulaglutide.
They found 55 cases of this infection in diabetic patients using SGLT2 inhibitors between 1 March 2013 and 31 January 2019.
The patients ranged in age from 33 to 87 years. Among them, 39 were men, and 16 were women.
The team found that the onset of infections ranged from 5 days to 49 months after the patients used SGLT2 inhibitors.
These people also experienced several other diabetic complications, including diabetic ketoacidosis, sepsis, and kidney injury.
On the contrary, only 19 cases of infection in patients using other diabetes drugs between 1984 and 31 January 2019.
The team says that the infection is a newly identified safety concern in diabetic patients receiving SGLT2 inhibitors.
Doctors who prescribe this type of drug should be aware of this possible complication and try to detect it in its early stages.
The study was published in the Annals of Internal Medicine and conducted by Susan J. Bersoff-Matcha et al.
If you care about diabetes, please read studies that not all whole grain foods could benefit people with diabetes, and green tea and coffee could help reduce death risk in diabetes.
For more information about nutrition, please see recent studies that blueberries strongly benefit people with metabolic syndrome, and results showing vitamin D could improve blood pressure in people with diabetes.
Copyright © 2023 Knowridge Science Report. All rights reserved.